Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

PETALING JAYA: Notion VTEC Bhd ’s weak performance is expected to persist in the upcoming quarters, in line with seasonally lower sales in the technology sector, says Hong Leong Investment Bank ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...

In 2002 Honda completely redesigned the 800 with a new chassis, sharper styling, underseat pipes and the firm’s variable valve timing technology (VTEC). Reviews were mixed, particularly from ...

And just to be clear, Merck is a company I like, which, I believe, has amazing fundamentals. You don't need me to make the bull case for Merck: 9 of the last 10 articles on Seeking Alpha have a ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Courtney Breen, senior analyst of U.S. biopharmaceuticals at Bernstein, discusses Merck's slump in the market following its halt of Gardasil and HPV vaccine shipments in China. February 04, 2025 at ...